175 related articles for article (PubMed ID: 20821746)
1. Transcriptional regulation of inducible nitric oxide synthase gene therapy: targeting early stage and advanced prostate cancer.
Coulter JA; Page NL; Worthington J; Robson T; Hirst DG; McCarthy HO
J Gene Med; 2010 Sep; 12(9):755-65. PubMed ID: 20821746
[TBL] [Abstract][Full Text] [Related]
2. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG
J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586
[TBL] [Abstract][Full Text] [Related]
3. Cell-selective gene silencing in prostate cancer LNCap cells using prostate-specific membrane antigen promoter and enhancer in vitro and in vivo.
Liu R; Sun J; Zhang Z; Xu Y
Cell Biol Int; 2012 Oct; 36(10):863-72. PubMed ID: 22612256
[TBL] [Abstract][Full Text] [Related]
4. Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment.
Worthington J; McCarthy HO; Barrett E; Adams C; Robson T; Hirst DG
J Gene Med; 2004 Jun; 6(6):673-80. PubMed ID: 15170738
[TBL] [Abstract][Full Text] [Related]
5. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation.
Coulter JA; McCarthy HO; Worthington J; Robson T; Scott S; Hirst DG
Gene Ther; 2008 Apr; 15(7):495-503. PubMed ID: 18256696
[TBL] [Abstract][Full Text] [Related]
6. Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer.
Furuhata S; Ide H; Miura Y; Yoshida T; Aoki K
Mol Ther; 2003 Mar; 7(3):366-74. PubMed ID: 12668132
[TBL] [Abstract][Full Text] [Related]
7. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells.
Puglisi MA; Cenciarelli C; Tesori V; Cappellari M; Martini M; Di Francesco AM; Giorda E; Carsetti R; Ricci-Vitiani L; Gasbarrini A
J Pathol; 2015 Aug; 236(4):479-90. PubMed ID: 25875314
[TBL] [Abstract][Full Text] [Related]
8. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.
Denmeade SR; Sokoll LJ; Dalrymple S; Rosen DM; Gady AM; Bruzek D; Ricklis RM; Isaacs JT
Prostate; 2003 Mar; 54(4):249-57. PubMed ID: 12539223
[TBL] [Abstract][Full Text] [Related]
9. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer.
Worthington J; Robson T; Scott S; Hirst D
Gene Ther; 2005 Oct; 12(19):1417-23. PubMed ID: 15902277
[TBL] [Abstract][Full Text] [Related]
11. Inducible nitric oxide synthase activity is essential for inhibition of prostatic tumor growth by interferon-beta gene therapy.
Olson MV; Lee J; Zhang F; Wang A; Dong Z
Cancer Gene Ther; 2006 Jul; 13(7):676-85. PubMed ID: 16470211
[TBL] [Abstract][Full Text] [Related]
12. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen.
Li Y; Tian Z; Rizvi SM; Bander NH; Allen BJ
Prostate Cancer Prostatic Dis; 2002; 5(1):36-46. PubMed ID: 15195129
[TBL] [Abstract][Full Text] [Related]
13. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor effects of a recombinant anti-prostate specific membrane antigen immunotoxin against prostate cancer cells.
Meng P; Dong QC; Tan GG; Wen WH; Wang H; Zhang G; Wang YZ; Jing YM; Wang C; Qin WJ; Yuan JL
BMC Urol; 2017 Feb; 17(1):14. PubMed ID: 28193277
[TBL] [Abstract][Full Text] [Related]
15. Enhanced aggressiveness of bystander cells in an anti-tumor photodynamic therapy model: Role of nitric oxide produced by targeted cells.
Bazak J; Fahey JM; Wawak K; Korytowski W; Girotti AW
Free Radic Biol Med; 2017 Jan; 102():111-121. PubMed ID: 27884704
[TBL] [Abstract][Full Text] [Related]
16. Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer.
Hattori Y; Maitani Y
Cancer Sci; 2006 Aug; 97(8):787-98. PubMed ID: 16800821
[TBL] [Abstract][Full Text] [Related]
17. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer.
Aaltoma SH; Lipponen PK; Kosma VM
Anticancer Res; 2001; 21(4B):3101-6. PubMed ID: 11712818
[TBL] [Abstract][Full Text] [Related]
18. Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.
Zeng H; Wei Q; Huang R; Chen N; Dong Q; Yang Y; Zhou Q
J Androl; 2007; 28(6):827-35. PubMed ID: 17522418
[TBL] [Abstract][Full Text] [Related]
19. PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth.
Su Y; Yu L; Liu N; Guo Z; Wang G; Zheng J; Wei M; Wang H; Yang AG; Qin W; Wen W
Cancer Lett; 2013 Sep; 338(2):282-91. PubMed ID: 23752065
[TBL] [Abstract][Full Text] [Related]
20. Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model.
Kranzbühler B; Sousa R; Prause L; Burger IA; Rupp NJ; Sulser T; Salemi S; Eberli D
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1418. PubMed ID: 34008909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
